TY - JOUR
T1 - Investigator-reported efficacy of Azelaic acid foam 15% in patients with papulopustular rosacea
T2 - Secondary efficacy outcomes from a randomized, controlled, double-blind, phase 3 trial
AU - Solomon, James A.
AU - Tyring, Stephen
AU - Staedtler, Gerald
AU - Sand, Meike
AU - Nkulikiyinka, Richard
AU - Shakery, Kaweh
N1 - Publisher Copyright:
© Cutis 2016.
PY - 2016
Y1 - 2016
N2 - Papulopustular rosacea (PPR) is characterized by centrofacial papules and pustules commonly associated with erythema. To compare investigator-reported efficacy outcomes for azelaic acid (AzA) foam 15% versus vehicle foam in PPR, a randomized, vehiclecontrolled double-blind phase 3 clinical trial was conducted at 48 US sites. Participants received AzA foam or vehicle foam for 12 weeks. Secondary efficacy outcomes included change in inflammatory lesion count (ILC), therapeutic response rate according to investigator global assessment (IGA), and change in erythema rating. This study was comprised of 961 participants with PPR. The results support the therapeutic superiority of AzA foam over vehicle foam.
AB - Papulopustular rosacea (PPR) is characterized by centrofacial papules and pustules commonly associated with erythema. To compare investigator-reported efficacy outcomes for azelaic acid (AzA) foam 15% versus vehicle foam in PPR, a randomized, vehiclecontrolled double-blind phase 3 clinical trial was conducted at 48 US sites. Participants received AzA foam or vehicle foam for 12 weeks. Secondary efficacy outcomes included change in inflammatory lesion count (ILC), therapeutic response rate according to investigator global assessment (IGA), and change in erythema rating. This study was comprised of 961 participants with PPR. The results support the therapeutic superiority of AzA foam over vehicle foam.
UR - http://www.scopus.com/inward/record.url?scp=85013984101&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013984101&partnerID=8YFLogxK
M3 - Article
C2 - 27814413
AN - SCOPUS:85013984101
SN - 0011-4162
VL - 98
SP - 187
EP - 194
JO - Cutis
JF - Cutis
IS - 3
ER -